All In MedTech

Device Trial Radar · NCT04927702

Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

48

Actual

Start

Jul 19, 2021

Primary completion

Jul 15, 2024

Study completion Aug 1, 2024

Sponsor

Lead sponsor
Acera Surgical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 16, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care. In participants with venous leg ulcers (VLUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with living cellular skin substitute (Apligraf®)

Conditions

  • Diabetic Foot Ulcer
  • Venous Leg Ulcer

Interventions

  • Synthetic Hybrid-Scale Fiber MatrixDevice

    A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.

  • Standard of CareDevice

    To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.

  • Living Cellular Skin SubstituteDevice

    An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For Diabetic Foot Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of WoundTime frame: 12 weeks
  2. For Venous Leg Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of WoundTime frame: 16 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • ILD Research Center

    Vista, California

  • University of Florida - Jacksonville

    Jacksonville, Florida

  • Barry University

    Miami Beach, Florida

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.